RCS - Arecor Therapeutics - Arecor Establishes New Scientific Advisory Board

Arecor TherapeuticsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nRSN8260Qa&default-theme=true

RNS Number : 8260Q  Arecor Therapeutics PLC  14 July 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

ARECOR ESTABLISHES NEW SCIENTIFIC ADVISORY BOARD OF WORLD LEADING EXPERTS IN
ORAL DRUG DELIVERY

-      Internationally recognised leaders will provide expert technical
guidance to support Arecor in its mission to develop a game-changing oral
delivery of peptides technology platform

 

Cambridge, UK, 14 July 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces the formation of its new Scientific Advisory Board of
internationally recognised experts in the fields of oral drug delivery and
peptide therapeutics.

 

Arecor is leveraging its significant formulation and product development
expertise to develop a game-changing novel technology platform for the oral
delivery of peptides with significantly improved bioavailability compared with
the state-of-the-art approaches available today. This would address a key
patient need in large and highly valuable markets such as diabetes and
obesity. These world leading specialist advisors will provide key technical
and strategic guidance as Arecor tackles the challenge of achieving effective
oral delivery of peptides, with the goal of unlocking the potential of oral
delivery for this increasingly important class of therapeutics.

 

Jan Jezek, Ph.D., Chief Scientific Officer of Arecor, said: "The challenge of
oral peptide delivery has persisted for decades, with even the most advanced
therapeutics on the market achieving less than 1% bioavailability. At present
nearly all peptide drugs are only injectable and there is well-established
evidence that their oral delivery would improve patient compliance and
adherence, reducing the overall healthcare burden and improving access. We are
delighted to welcome this exceptional group of experts to our Scientific
Advisory Board, who bring unparalleled expertise in our mission to develop a
novel oral delivery of peptides platform that can address the current
significant unmet patient need."

 

Members of the Arecor Scientific Advisory Board include:

 

David Brayden, PhD, is a Full Professor of Advanced Drug Delivery at the
School of Veterinary Medicine, University College Dublin (UCD) and a Senior
Fellow of the UCD Conway Institute. His research focuses on oral peptide
delivery and nanomedicines, with over 300 research publications and 12 patents
in these areas. He is an elected Fellow of both the Controlled Release Society
and the American Association of Pharmaceutical Scientists, and is an elected
member of the Royal Irish Academy. Dr. Brayden is co-lead PI on the Research
Ireland Centre for Medical Devices (CURAM) and current coordinator of
BUCCAL-PEP, an EU Horizon Europe grant on buccal administration of peptides.
He serves as Chief Editor of "Frontiers in Drug Delivery" and was appointed by
Ireland's Minister of Health as Chairperson to the National Research Ethics
Committees on Clinical Trials (D). Dr. Brayden obtained his PhD from the
University of Cambridge, followed by a postdoctoral fellowship at Stanford
University, CA, USA, before spending 10 years at Elan Biotechnology Research.

 

Randy Mrsny, PhD, is Professor of Drug Delivery at the University of Bath,
where his research examines mechanisms controlling trans-epithelial migration
and tight junction regulation, as well as the fate of biopharmaceuticals in
subcutaneous and intramuscular spaces. He was the Founder and Chief Scientific
Officer of Applied Molecular Transport (now Cyclo Therapeutics), which
directed the advancement of technology utilising endogenous pathways for
efficient epithelial transcytosis. His career includes leadership roles at
ALZA Corporation, Genentech, and as founder of Trinity BioSystems and Unity
Pharmaceuticals. Dr Mrsny has served as President of the Controlled Release
Society, been selected to its College of Fellows, and received its Founders
Award. He was selected for the Medicine Maker 100 power list in 2015 and 2016.
Dr. Mrsny has a BSc in Biochemistry and Biophysics from the University of
California and a PhD in Human Anatomy and Cell Biology from the UCD School of
Medicine.

 

Christopher Porter, PhD, is Director of the Monash Institute of Pharmaceutical
Sciences (MIPS) at Monash University, with research focused on the absorption
distribution and elimination profiles of drugs, as well as developing novel
formulation approaches to optimise these profiles. He has published over 270
peer reviewed papers, his research programmes have attracted over $35m in
funding, and is an inventor on more than 15 separate patent families. He is a
Clarivate Analytics highly cited researcher, a fellow of the American
Association of Pharmaceutical Scientists and an Editorial Board member for
Molecular Pharmaceutics, Pharmaceutical Research and the Journal of
Pharmaceutical Sciences. Dr. Porter obtained his BPharm and PhD in
Pharmaceutics from the University of Nottingham.

 

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGMNNFGGKZG